FAZ reports on the SHS portfolio company Selfapy, which offers online therapies for depression, anxiety and eating disorders. This enables patients who need acute help to bridge long waiting times until a doctor’s appointment.

The M&A consultancy Clairfield and Luther Rechtsanwaltsgesellschaft prepared this informative study with the support of the German Medical Technology Association (BVMed) and the German Engineering Federation (VDMA). The study gives you an overview of the current development of medical technology in Germany, Europe, the USA and Asia: from a legal, technical and transaction-oriented perspective. Due […]

Digital healthcare Selfapy GmbH (SHS V Fund) There are lots of reasons why some people might be going through a mental crisis. Contact with family and friends can be an important support in times of crisis. Now, however, with rules for social distancing in effect, this valuable support cannot continue. The affected patients need to […]

Pharmaceutical services c-LEcta GmbH (SHS III Fund) Another important building block for successfully managing the coronavirus pandemic is the development of effective drugs and vaccines. SHS invests in pharmaceuticals suppliers that can leverage high-performance solutions to help accelerate the development of pharmaceuticals products. c-LEcta GmbH, based in Leipzig, Germany, is one of the leading industrial […]

Pharmaceutical services Single Use Support GmbH (SHS V Fund) The trip for medical substances from the production site to the patient needs to be absolutely secure – the robust products by Single Use Support (Kufstein, Austria) ensure all-round protection of bagged liquid medicines: During filling, freezing, thawing, storage and transportation. A leading US biotech company […]

Medical technology TNI Medical AG (SHS III Fund) The availability of sufficient ventilatory support capacity for COVID-19 patients is an extremely critical issue for most of the healthcare systems worldwide. Products by TNI Medical AG, of Würzburg, Germany, contribute to this effort. The innovative technology developed by TNI for the non-invasive ventilatory support (high-flow therapy) […]

Medical technology Novo Klinik-Service GmbH (SHS IV Fund) Novo Klinik-Service GmbH, headquartered in Bergheim near Cologne, Germany, develops innovative products for the fixation and stabilization of endotracheal tubes in invasively ventilated patients. Given the current situation in hospitals, safe and easy-to-use solutions are particularly welcomed by nursing staff. In order to support their lung function, […]

Diagnostics GNA Biosolutions GmbH (SHS IV Fund) Test, test and test again! Diagnostics play a critical role in combating the current coronavirus pandemic (SARS-CoV-2). The quick and comprehensive identification of infected persons is a crucial contribution to the detection and critical disruption of chains of infection. With its ultra-fast PCA (pulse-controlled amplification) technology, GNA, headquartered […]

Diagnostics ndd Medizintechnik AG (SHS IV Fund) Based on what we now know, people with impaired lung function belong to the high-risk group – and not just now, during the current pandemic. Not only do COPD patients (some 50% of whom are unaware of their disease) have impaired or critical lung function, but so do […]

Dr. André Zimmermann, partner at SHS, was a guest in the BVK expert talk. Deputy Managing Director Swantje von Massenbach spoke to him about investments in the health sector, such as medical technology or diagnostics. Among other things, this included a rapid corona test that can achieve a result within 15 minutes with comparable accuracy to tests that still take several hours today. For portfolio companies and SHS investors, what is known as impact investing is particularly important. This means that investments have positive effects on health, the environment or society. You can learn more about this in the video.

With the Investor Network Tyrol, the Tyrolean location agency brings companies and start-ups together with the right investors. In a discussion between Klaus Grössinger from the Investor Network of the Tyrolean location agency and Friedrich Baldinger from the Tübingen-based medical technology and life science investor SHS, they will explain how this works in practice.

“The high demand for digital health offers should not hide the fact that the industry is facing enormous risks,” says Cornelius Maas, SHS Senior Investment Manager, in a guest article in Handelsblatt.